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Effects of a novel elastase inhibitor, ONO-5046, on nephrotoxic serum
nephritis in rats. ONO-5046 is a potent, specific and intravenously active
inhibitor of neutrophil elastase. To examine the role of elastase in
glomerulonephritis, we tested the effects of ONO-5046 on nephrotoxic
serum (NTS) nephritis in a rat model of the disease in humans. Rats were
administered ONO-5046 or phosphate-buffered saline (PBS) intraperito-
neally 24 hours prior to injection of NTS, and they were then given equal
doses of ONO-5046 or PBS three hours and 1, 2, 3, 4, 5 and 6 days later.
Compared with the control groups, ONO-5046 significantly reduced
proteinuria and hematuria, and suppressed the formation of crescentic
glomeruli in a dose-dependent manner. Our results suggest that neutro-
phil elastase participates in NTS nephritis by degrading glomerular
basement membrane proteins, and that the elastase inhibitor, ONO-5046,
suppresses crescentic formation and glomerular injury caused by elastase.
Nephrotoxic serum (NTS) nephritis is produced in animals by
the administration of heterologous antibody directed against
glomerular basement membrane (GBM). Such NTS nephritis is a
well-established experimental model of human glomerular im-
mune injury resulting in glomerulonephritis (GN) [1]. The glo-
merular lesions induced by NTS vary with species. The Wistar-
Kyoto rat is susceptible to the induction of a crescentic GN
following small doses of NTS [2]. Heterologous-phase NTS-
induced glomerular injury in these animals is usually followed by
a transient influx of polymorphonuclear leukocytes (PMN) within
minutes of the injection of sufficient NTS [3]; the accumulation of
PMNs peaks within a few hours. Activation of PMN adherent to
the GBM leads to the release of the cationic neutral serine
proteases, elastase and cathespin G, which are present in the
azurophilic granules of PMN [4]. Evidence for the involvement of
these neutral serine proteases in glomerular injury has been
provided by a number of studies. In vitro studies have shown that
elastase degrades several constituents of the GBM, including
fibronectin, laminin, and collagen type IV [5–7]. The in vivo
perfusion of the kidneys with active elastase has been shown to
produce severe proteinuria [8].
Although plasma contains such powerful anti-proteinases as
alpha 1-proteinase inhibitor and alpha 2-macroglobulin, PMN
have been reported to degrade tissue components even in their
presence [9]. It has been proposed that the ability of these
anti-proteinases to inhibit PMN elastase is circumvented by the
exclusion of these protease inhibitors from close contact between
the migrating PMNs and the extracellular matrix [10, 11]. In
contrast to these macromolecules, a low molecular weight inhib-
itor of neutrophil elastase might be able to achieve such close
contact. ONO-5046, N-[2-[4-(2,2-Dimethylpropionyloxy) phenyl-
sulfonylamino]benzoyl] aminoacetic acid, is a potent, specific and
intravenously-active human neutrophil elastase inhibitor [12].
ONO-5046 has also been shown to inhibit rabbit, rat, hamster and
mouse leukocyte elastase [12]. A small molecule, ONO-5046 may
be effective against the elastase of the GBM in NTS nephritis.
We therefore examined the possible inhibitory effect of ONO-
5046 on the development of glomerular injury in WKY rats with
NTS nephritis.
METHODS
Animals
Inbred male WKY rats aged 8 weeks were obtained from
Charles River Japan Inc. (Atsugi, Kanagawa, Japan). Rats were
housed individually in metabolic cages to obtain urine samples.
They were fed standard rat chow and given free access to water
throughout the experiment.
Rabbit anti-rat glomerular basement membrane anti-serum
Rat GBM that was obtained from perfused renal cortices [13]
was digested with trypsin (Sigma Chemical Co., St. Louis, MO,
USA) for three hours at 37°C. After heating at 60°C for 30
minutes, the mixture was centrifuged at 76,000 3 g for one hour,
and the supernatant was lyophilized. For the production of NTS,
white rabbits were subcutaneously injected with the lyophilized
sample emulsified in complete Freund’s adjuvant. Injections were
repeated in the second, fourth and sixth weeks. Rabbits were bled
in the seventh week and the serum was separated. Sera with
nephrotoxic potency, which induced proteinuria in rats one day
after the intravenous injection of 0.2 ml of antiserum, were
pooled. The pooled antiserum was inactivated at 56°C for 30
minutes, and stored at 220°C until use.
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ONO-5046
ONO-5046 was supplied by Ono Pharmaceutical Co., Ltd.
(Osaka, Japan). It was dissolved in PBS (pH 7.4) immediately
prior to use.
Experimental design
Rats (N 5 20 in each group) received an intraperitoneal
injection of ONO-5046 of either 75 mg/kg, 300 mg/kg, or 600
mg/kg. The control group similarly received intraperitoneal injec-
tions of PBS. Twenty-four hours later, the rats were injected with
0.2 ml NTS through the tail vein. They were administered the
same dose of ONO-5046 or of PBS intraperitoneally three hours
after NTS injection and again at 1, 2, 3, 4, 5 and 6 days later. Five
rats in each group were killed by axillar bleeding at 1, 3, 5, or 7
days after the injection of NTS.
Histological examination
At the time of sacrifice, each kidney specimen was divided into
three parts for examination by light, electron and immunofluores-
cence microscopy.
Light microscopy
Each specimen was fixed in buffered formalin and embedded in
paraffin for light microscopic examination. Sections 2 to 3 microns
thick were stained with hematoxylin-eosin (HE), periodic acid
Schiff (PAS), periodic acid silver methenamine (PAM), and
Masson-trichrome and PAM-Masson. The percentage of crescen-
tic glomeruli was calculated for each rat.
Immunofluorescence microscopy
Each specimen was immediately embedded in OCT medium
(Miles Laboratories, Elkhart, IN, USA) and frozen in a mix of
Fig. 1. Urinary protein excretion in WKY rats
treated with ONO-5046 plus nephrotoxic serum
nephritis (NTS). Rats were administered 75
mg/kg ONO-5046 (n—n), 300 mg/kg ONO-5046
(e—e), 600 mg/kg ONO-5046 (r—r), or PBS
(c—c), intraperitoneally, and injected 24 hours
later with 0.2 ml NTS. They were administered
the same dose of ONO-5046 or of PBS
intraperitoneally 3 hours after NTS injection,
and again at 1, 2, 3, 4, 5 and 6 days later. Data
represent mean 6 SD. q P , 0.001 vs. control;
w P , 0.001 vs. 75 mg/kg ONO-5046; I P ,
0.001 vs. 300 mg/kg ONO-5046.
Table 1. Hematuria in WKY rats treated with ONO-5046 plus NTS
ONO-5046
Days after NTS injection
1 3 5 7
N Neg Pos N Neg Pos N Neg Pos N Neg Pos
0 20 20 0 15 15 0 10 0 10 5 0 5
(0%) (0%) (100%) (100%)
75 mg/kg 20 20 0 15 15 0 10 5 5b 5 3 2
(0%) (0%) (50%) (40%)
300 mg/kg 20 20 0 15 15 0 10 8 2a 5 4 1b
(0%) (0%) (20%) (20%)
600 mg/kg 20 20 0 15 15 0 10 8 2a 5 5 0a
(0%) (0%) (20%) (0%)
Experimental procedures are described in the Methods section. Abbreviations are: Neg, negative; Pos, positive; N number of rats; NTS, nephrotoxic
serum nephritis.
Hematuria was scored as positive (1 to 111) or negative (2 to 6).
a P , 0.01 vs. control
b P , 0.05 vs. control
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Fig. 2. Light micrograph showing glomeruli of the control group (A) and the 300 mg/kg ONO-5046 group (B) on day 7. The control group shows
mononuclear cell proliferation, exudative changes and crescentic formation. The ONO-5046 group shows a slight increase in mononuclear cells.
(Original magnification 3 400, Periodic acid-Schiff stain.)
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acetone and dry ice. Frozen sections (2 to 3 microns) were cut in
a cryostat and stored at 280°C until use. Cryostat sections cut
serially were rinsed in PBS for 15 minutes and fixed in absolute
acetone for 10 minutes. FITC-conjugated rabbit anti-rat IgG,
FITC-conjugated goat anti-rat C3, FITC-conjugated goat anti-rat
fibrinogen and FITC-conjugated goat anti-rabbit immunoglobu-
lins (Cappel, Malverne, PA, USA) were used for direct immuno-
fluorescence. The presence of rat granulocytes, monocytes or
macrophages was examined immunohistochemically on frozen
tissue specimens by using monoclonal antibodies MRCOX-41
(Biomedicals AG, Rheinstrasse, Switzerland).
Electron microscopy
Specimens for electron microscopy were fixed in 2.5% glutar-
aldehyde, followed by osmium tetraoxide, and embedded in Epon
812. Ultrathin sections stained with tannic acid and lead citrate
were examined.
Urinalysis
The amount of protein excreted in the urine per 24 hours was
determined using the Bio-Rad Protein Assay (Bio-Rad Labora-
tories, Richmond, CA, USA). Occult blood was measured using
N-Multistix SG-L (Bayer-Sankyo Co., LTD., Tokyo, Japan). The
amount of occult blood present was graded as 2, 6, 1, 11, or
111.
Statistical analysis
Numerical data are expressed as the mean 6 SD. Significant
differences were assessed using Student’s t-test, the chi-square
test, and Fisher’s exact test for fourfold tables, where appropriate.
A level of P , 0.05 was accepted as statistically significant.
RESULTS
Effect of ONO-5046 on proteinuria
The amount of protein excreted in the urine increased mark-
edly after day 5 in the control group and in the ONO-5046 (75
mg/kg and 300 mg/kg) groups but not in the group given 600
mg/kg ONO-5046 (Fig. 1). In the control group, urinary protein
excretion increased to 62 mg/day on day 7. This increase was
significantly suppressed in all of the groups administered ONO-
5046, and in a dose-dependent manner (Fig. 1).
Effect of ONO-5046 on hematuria
As shown in Table 1, hematuria was noted frequently in rats
administered PBS. This hematuria was significantly suppressed on
days 5 and 7 in all groups administered ONO-5046.
Histology and immunohistochemistry
In the control group glomerular lesions were induced by the
intravenous injection of 0.2 ml NTS on day 3; these were
characterized by endocapillary hypercellularity. In this group of
rats mesangial proliferation, severe necrotizing lesions, and
marked crescentic formation were observed on day 5 and there-
after. These alterations, however, were not observed in the
ONO-5046 groups (Figs. 2 and 3). In the immunofluorescence
study, rabbit IgG stained along the capillary walls of both control
and ONO-5046 rats in a linear pattern throughout the experiment
(Fig. 4). Although there was a gradual decrease in the intensity of
rabbit IgG throughout the experiment in each group, there was no
significant change in the intensity of IgG in any group. A small
number of PMN were noted in the glomerular capillaries on days
1 and 3. The glomerular accumulation of monocytes/macrophages
increased gradually in the control group and the 600 mg/kg
ONO-5046 group (13.3 6 6.5 and 11.5 6 6.4 cells/glomerular
cross-section at day 1, 23.2 6 6.5 and 21.0 6 5.9 cells/glomeru-
lar cross-section at day 3, 26.2 6 8.8 and 25.1 6 4.7 cells/
glomerular cross-section at day 5, and 24.5 6 7.2 and 21.7 6 7.7
cells/glomerular cross-section at day 7, respectively (Fig. 5). There
was no significant difference in the numbers of monocytes/
macrophages in any group.
Effect of ONO-5046 on crescentic formation
As shown in Figure 6, the frequency of crescentic glomeruli was
significantly suppressed in the ONO-5046 groups, in a dose-
dependent manner as compared with the control group. The
suppression of crescentic glomeruli was observed on day 5, and
was most pronounced on day 7.
DISCUSSION
The glomerular injury induced by NTS varies depending on the
species of animal tested, the age and sex of the recipient, the
amount and type of NTS used, and the duration of the disease
[14]. A very small dose of NTS induces severe proliferative and
necrotizing GN with crescentic formation in WKY rats [2].
Kawasaki et al [15] reported that crescentic GN in WKY rats was
characterized by the early infiltration of CD8 positive cells in
glomeruli; those authors suspected that the increased susceptibil-
ity of WKY rats to NTS may be unrelated to complement- or
PMN-related mechanisms of glomerular injury, but rather, related
to a CD8 positive cell-related injury. In contrast, we found that
pretreatment with ONO-5046, an inhibitor of neutrophil elastase
[12], significantly reduced crescentic formation in a dose-depen-
dent manner. This suggests that PMN, or at least neutrophil
elastase, participates in the glomerular injury in NTS nephritis.
This study showed that a small number of PMN accumulated in
the glomerular capillaries on days 1 and 3 and that the glomerular
accumulation of monocytes/macrophages increased gradually
through days 3, 5, and 7. Fujinaka et al [16] also reported the
infiltration of PMN in the glomerular capillaries at one hour and
days 1 and 3 after NTS injection in crescentic GN of WKY rats.
Wada et al [17] reported that the decrease of the number of
monocytes/macrophages in glomeruli of WKY rats by administer-
ing specific polyclonal neutralizing anti-monocyte chemotactic
and activating factor/monocyte chemoattractant protein-1
(MCAF/MCP-1) prevented crescentic formation, thereby de-
creasing the excreted amounts of protein to normal levels on days
3 and 6. Furthermore, Werb and Gordon [18] showed that
stimulated macrophages secreted elastase. Jensen et al [19, 20]
also indicated that human monocytes and macrophages have
elastolytic activity, which is mainly caused by cell surface related
PMN elastase. On the basis of the above results, our study
suggests that PMN elastase, which is secreted not only by PMN
but also by monocytes/macrophages, induces significant protein-
uria after 3 days and continues to do so. Although we did not
investigate experiments using various doses of NTS, it is possible
that, in WKY rats, the mechanism of the glomerular lesions
induced by NTS may vary according to the amount of NTS
administered.
Heparan sulphate, the anionic side chain of heparan sulphate
proteoglycans (HSPG), is a major determinant of the negative
charge on HSPG. Elastase is a highly cationic protein at neutral
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Fig. 3. Electron micrograph showing glomeruli of the control group (A) and the 300 mg/kg ONO-5046 group (B) on day 5. In the control group,
crescentic formation, adhesion and sclerotic lesion are observed in the glomerulus. The ONO-5046 group shows a slight increase in mononuclear cells
A, Original magnification 34000; B, original magnification 31000).
pH; the binding of elastase to the GBM probably occurs by charge
interaction. It has recently been reported that elastase degrades
HSPG of subendothelial matrix in vitro, suggesting that a proteo-
lytic cleavage of HSPG may be involved in the PMN-associated
proteinuria [21, 22]. Furthermore, Schrijver et al [23] showed that,
in NTS nephritis in beige mice, a deficiency of leukocyte neutral
Fig. 4. Immunofluorescence micrograph
showing glomerular deposition of rabbit IgG.
Rabbit IgG is distributed in a linear pattern
along glomerular basement membrane in both
the control group (A) and the ONO-5046 group
(B) on day 1 (original magnification 3400).
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proteinases prevents the induction of albuminuria in the heterol-
ogous phase, suggesting a role for the PMN enzymes. Interruption
of the GBM, probably caused in part by lysosomal enzymes,
especially elastase, in the PMNs may cause hematuria [24]. Our
findings that the elastase inhibitor, ONO-5046, significantly re-
duced proteinuria and hematuria in rats in a dose-dependent
manner, suggests that the degradation of GBM components may
be involved in elastase-induced proteinuria in NTS nephritis.
In summary, this study has provided evidence on the role of
PMN elastase, which is secreted not only by PMN but also by
monocytes/macrophages in the acute phase of crescentic GN.
Thus, the administration of an inhibitor to PMN elastase would be
a key to future treatment of PMN, monocyte, or macrophage-
related human GN.
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